Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences >

Biotech Values

RSS Feed
      Hide Sticky   Hide Intro
Moderator: DewDiligence Assistants: Biowatch
Search This Board:
Last Post: 10/20/2014 9:50:19 PM - Followers: 1119 - Board type: Free - Posts Today: 63
PostSubject
#183000  Sticky Note In lieu of acquiring SHPG, ABBV authorized a DewDiligence 10/20/14 06:05:42 PM
#182996  Sticky Note Enanta Pharmaceuticals Provides Update on its Collaboration Agreement steveporsche 10/20/14 05:12:54 PM
#182991  Sticky Note ABBV/ENTA—From ACG presentation on TURQUOISE-2 study: DewDiligence 10/20/14 04:02:24 PM
#182971  Sticky Note The point was not that it is the John Tucker 10/20/14 01:06:33 PM
#182951  Sticky Note CELG ABBV > First Detailed Look at Celgene biocqr 10/20/14 10:21:27 AM
#182950  Sticky Note NLNK > NewLink in $1 bln deal with biocqr 10/20/14 09:20:52 AM
#183008   Basic points: WorstLuck 10/20/14 09:50:19 PM
#183007   Testing for Cancer With a Single Blood Sample biocqr 10/20/14 09:31:02 PM
#183006   Quiz (low difficulty): Why didn’t ENTA establish the DewDiligence 10/20/14 08:41:56 PM
#183005   ENTA—Based on this new information and the return DewDiligence 10/20/14 08:41:23 PM
#183004   ENTA Based on this new information and the return WorstLuck 10/20/14 06:54:36 PM
#183003   From a cursory look, it seems like a DewDiligence 10/20/14 06:32:07 PM
#183002   I find it interesting.... not that it means anything.... willyw 10/20/14 06:28:29 PM
#183001   ENTA—The paragraph in today's PR on what will DewDiligence 10/20/14 06:07:50 PM
#183000   In lieu of acquiring SHPG, ABBV authorized a DewDiligence 10/20/14 06:05:42 PM
#182999   $ENTA Was there anything else you found masterlongevity 10/20/14 06:01:29 PM
#182998   ABT-450’s 30% value share of ABBV/ENTA’s 3-DAA regimen DewDiligence 10/20/14 05:36:28 PM
#182997   ENTA—Co-Development Option on Next-Generation Protease Inhibitor ABT-4 DewDiligence 10/20/14 05:32:31 PM
#182996   Enanta Pharmaceuticals Provides Update on its Collaboration Agreement steveporsche 10/20/14 05:12:54 PM
#182995   One my friend, a mid-size company CEO said: zipjet 10/20/14 04:41:01 PM
#182994   (what if) ACHN's production lots contain 1%, 0.1%, frontiers 10/20/14 04:36:20 PM
#182993   CVM seeks warrant-laden financing: DewDiligence 10/20/14 04:35:09 PM
#182992   ENTA—New all-time intra-day ($47.00) and closing ($46.59) highs. DewDiligence 10/20/14 04:14:59 PM
#182991   ABBV/ENTA—From ACG presentation on TURQUOISE-2 study: DewDiligence 10/20/14 04:02:24 PM
#182990   NVS’ PR re unanimous panel vote for Secukinumab DewDiligence 10/20/14 03:18:20 PM
#182989   AD company genisi 10/20/14 02:51:52 PM
#182988   the point is that the release of the frontiers 10/20/14 02:44:49 PM
#182987   FDA advisory panel backs NVS’ Secukinumab for psoriasis DewDiligence 10/20/14 02:34:05 PM
#182986   OPHT—Decision Resources is moderately bullish on Fovista: DewDiligence 10/20/14 02:22:24 PM
#182985   Whether or not the ACH-3422 monotherapy data are DewDiligence 10/20/14 02:18:53 PM
#182984   #AD drugs masterlongevity 10/20/14 02:12:41 PM
#182983   what’s unique about ACH-3422 is that some sell-side frontiers 10/20/14 01:59:45 PM
#182982   ACHN—…your statement applies to every single HCV nuke DewDiligence 10/20/14 01:47:28 PM
#182981   Well then, I have read the patent frontiers 10/20/14 01:45:41 PM
#182980   the biggest risk is that ACH-3422 simply doesn’t frontiers 10/20/14 01:42:14 PM
#182979   Exactly—that’s why it doesn’t illuminate anything for us DewDiligence 10/20/14 01:39:42 PM
#182978   ACHN—To keep this thread in perspective: My view DewDiligence 10/20/14 01:35:36 PM
#182977   What am I missing? frontiers 10/20/14 01:32:46 PM
#182976   Who listened to the Copaxone SCOTUS hearing (#msg-107338761)? DewDiligence 10/20/14 01:29:06 PM
#182975   The advantages will keep the generics cos at John Tucker 10/20/14 01:26:49 PM
#182974   ACHN…these [deuteration] benefits were unexpected and surprising. Isn’t DewDiligence 10/20/14 01:21:28 PM
#182973   On their point regarding two legal opinions they frontiers 10/20/14 01:18:48 PM
#182972   Ok but .... frontiers 10/20/14 01:16:37 PM
#182971   The point was not that it is the John Tucker 10/20/14 01:06:33 PM
#182970   Agree 100%. willyw 10/20/14 12:23:41 PM
#182969   ENTA—It would seem to me that the value DewDiligence 10/20/14 12:13:23 PM
#182968   It would seem to me that the value willyw 10/20/14 12:08:22 PM
#182967   I've been watching this morning. willyw 10/20/14 12:07:51 PM
#182966   The Telegraph ilpapa 10/20/14 12:07:03 PM
#182965   A patent is just a piece of paper frontiers 10/20/14 12:06:12 PM
#182963   Some people wonder if Abbvie may now turn Bickema 10/20/14 11:58:25 AM
#182962   One my friend, a mid-size company CEO said: caravon 10/20/14 11:58:15 AM
#182961   Brand new AGN slide deck opposing VRX merger: DewDiligence 10/20/14 11:55:28 AM
#182960   Some people wonder if Abbvie may now turn willyw 10/20/14 11:51:31 AM
#182958   ENTA - I would have guessed that was Bickema 10/20/14 11:49:19 AM
#182957   $ACHN drug is very close to old $IDX frontiers 10/20/14 11:47:16 AM
PostSubject